Physician profile
Brooke Spalt
NPI 1043094881
$4,835.90
in general payments reported to CMS, 2019-2025
36 companies · $2,142 in 2025
The $2,142 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $453 · 2024: $2,241 · 2025: $2,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $803.41 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $263.47 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $259.96 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $229.44 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.92 | 2023-2025 | Xifaxan |
| Amgen INC. | $137.30 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.78 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $130.38 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $129.01 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $123.89 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $123.30 | 2023-2025 | Trintellix |
| Dexcom, INC. | $110.11 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $108.24 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $105.49 | 2023-2025 | Rexulti |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Spalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.